Review Session Exam One

Question 1

4 QUESTIONS ON the EXAM FM LECTURE

Answer 1

LO 3, 5, 6, 7 FOCUS ON

Question 2

3: MOAS
5: Treatment Plan (combos recommended)
6: Nonpharmacologic and EULAR recommendations
7: Role of pharmacologic agents, which ones are approved + brand names + spelling

Question 3

1 QUESTION ON the EXAM OA INTRO LECTURE

Answer 3

LO 3 FOCUS ON

Question 4

3: How do we differentiate forms of OA, findings under specific disease state

Question 5

3 QUESTION ON the EXAM OA Pathophys LECTURE

Answer 5

LO 2, 3, and 5 FOCUS ON

Question 6

2: Risk factors for developing OA
3: What are the changes in cartilage or joints in OA
5: Usually S/S of OA

Question 7

12 QUESTION ON the EXAM OA Therapy LECTURE
+2 covered under other sections

Answer 7

LO 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10

Question 8

1: Monitoring parameters, disease specific instruments WOLMAC
2: Non-drug treatment OA
3: MOA of NSAIDs
4: 3 QUESTIONS: MOA of Side Effects, Risk factors of developing side effects, Which NSAID is related to most/least to each side effect
5: Risk for specific patient with NSAIDs (not a specific question)
6: PK/PD to common to most NSAIDs
7: Drugs that can interact with NSAIDs, know the effect if it increases or decreases
8: 2 QUESTIONS: MOA of Non-NSAID analgesics and topical therapy aka what is available, and what is the MOA substances, and SPELL the topical options (ingredient)
9: commonly used nutraceuticals and the best combo in the study
10: adv vs disadvantages of drugs to treat OA in different situations, patient factors

Question 9

Pathophys RA 4 QUESTIONS kinda +1
1: epidemiology of RA
2: categories of classification
4: how would you monitor RA disease activity
5: compare RA and OA

Question 10

Therapy RA 12 QUESTIONS +1
1: monitor therapy, parameters, assessment tools
2: ACR approaches to treatment focus on initial choice with the different severities
4: know MOA of all biologics and be able to tell which type of mab it is
6: 2 QUESTIONS: side effects of RA drugs and appropriate monitoring, and how to minimize their occurance
7: 2 QUESTIONS: ROA of oral vs injectable (do not need to know SUB q vs IV), and onset of action (ex. corticosteroids has a fast onset preferable for bridging)
8: drugs that are given less frequently than daily (methotrexate)
9: which drugs can be combined and which cannot be
10: pregnancy considerations and action if a patient becomes pregnant (cholestyramine for Leflunomide)
11: 2 QUESTIONS: how do you screen for tb and immunization considerations (live vs not alive)